Trial · NCT02082912
NMDA Receptors in Motor Learning in Humans
NCT02082912, Phase 2, Completed, Emory University; results first posted 2015-04-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NMDA Receptors in Motor Learning in Humans. Trials, record NCT02082912. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02082912
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NMDA Receptors in Motor Learning in Humans
- NCT number
- NCT02082912
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 14 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Stroke
- Interventions
- D-cycloserine, Placebo, HandMentor Pro
- First posted
- 2014-03-10
- Last updated
- 2018-11-07
- Results first posted
- 2015-04-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Grip Strength of Affected Hand | Baseline, Day 30 | Hand-grip strength was assessed using the whole hand and was defined as the average of 3 trials using a calibrated Jamar dynamometer (Jamar Dynamometer, Asimow Engineering Co., Santa Monica, CA), with the elbow flexed to 90º and the forearm in a neutral position. This is the standardized method for measuring hand-grip strength with a Jamar dynamometer recommended by the American Society of Hand Therapists. An increase in values means that grip strength is improving. |
| Secondary | Percentage of Stroke Impact Scale (SIS) Categories Meeting Change Criteria | Baseline, Day 30 | The percentages of Stroke Impact Scale (SIS) physical domain categories meeting criteria for Minimal Clinically Important Difference (MCID) are presented here. The SIS has 59 items in 8 domains of function where respondents rate their degree of difficulty on a 5-point scale, plus a 9th category for stroke recovery (one item, scored from 0 to 100). Scores for each domain are generated so that total scores for each domain range from 0 - 100, where higher scores indicate less difficulty and more recovery. A change of more than 4.5 to 17.8 for the domains was considered a MCID. A higher percentage of SIS categories meeting the MCID criteria indicates increased improvement in that study arm. |
| Secondary | Center for Epidemiologic Studies Depression (CES-D) Scale Score | Baseline, Day 30 | Depressive symptoms were assessed with the Center for Epidemiologic Studies Depression (CES-D) Scale. The CES-S has 20 items rated on a scale of 0 to 3. Total scores range from 0 to 60 with higher scores indicating more depressive symptoms, and a score of 16 or above indicates depression. Baseline scores are presented in the Outcome Measure Data Table and the impact of the study arm at Day 30 is presented in the statistical analysis section. |
| Secondary | Display Enhanced Testing for Concussions and Mild Traumatic Brain Injury (mTBI) (DETECT) System Score | Baseline, Day 30 | Using a computer, helmet with heads-up-display, headphones with audio inputs, and an input unit with two buttons ("Yes" and "No"), the DETECT system combines an immersive environment with neuropsychological tests to assess mTBI. The DETECT software consists of a series of tests evaluating information processing speed, episodic memory, and working memory. Performance is scored based on response type (correct, incorrect, and missing) and response time. Test results are displayed using an internal algorithm that is based on the probability of impairment. Mean baseline z-scores are presented in the Outcome Measure Data Table and the impact of the study arm at Day 30 is presented in the statistical analysis section. A z-score of 0 represents a healthy individual; scores above 0 are the number of standard deviations above the mean, indicating more errors, taking more time, and thus having a higher probability of mild cognitive impairment. |
| Secondary | Number of Blocks Moved During the Box and Block Test (BBT) of Affected Arm | Baseline, Day 30 | Change in functional motor task performance of the arm affected by the stroke was assessed with the Box and Block Test (BBT). The BBT involves dexterous manipulation of objects and voluntary motor control, which improves with upper limb recovery following stroke. The number of blocks moved within 60 seconds are counted. Baseline scores of the mean number of blocks moved are presented in the Outcome Measure Data Table and the impact of the study arm at Day 30 is presented in the statistical analysis section. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Grip Strength of Affected Hand | Baseline, Day 30 | Participants completing the study are included in this analysis. | Newton | MEAN |
| SECONDARY | Percentage of Stroke Impact Scale (SIS) Categories Meeting Change Criteria | Baseline, Day 30 | Participants completing the study are included in this analysis. | percentage of category scores | NUMBER |
| SECONDARY | Center for Epidemiologic Studies Depression (CES-D) Scale Score | Baseline, Day 30 | Participants completing the study are included in this analysis. | units on a scale | MEAN |
| SECONDARY | Display Enhanced Testing for Concussions and Mild Traumatic Brain Injury (mTBI) (DETECT) System Score | Baseline, Day 30 | Participants with complete information for the DETECT measurement are included in this analysis. Two participants had missing values dues to technical issues with the instrument. | z-score | MEAN |
| SECONDARY | Number of Blocks Moved During the Box and Block Test (BBT) of Affected Arm | Baseline, Day 30 | Participants completing the study are included in this analysis. | blocks per minute | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Grip Strength of Affected Hand | D-cycloserine | Baseline | 3.95 | Standard Deviation 2.96 | Newton |
| Grip Strength of Affected Hand | Placebo | Baseline | 5.72 | Standard Deviation 3.98 | Newton |
| Grip Strength of Affected Hand | D-cycloserine | Day 30 | 4.90 | Standard Deviation 3.56 | Newton |
| Grip Strength of Affected Hand | Placebo | Day 30 | 8.44 | Standard Deviation 4.90 | Newton |
| Percentage of Stroke Impact Scale (SIS) Categories Meeting Change Criteria | D-cycloserine | 44.4 | percentage of category scores | ||
| Percentage of Stroke Impact Scale (SIS) Categories Meeting Change Criteria | Placebo | 24.1 | percentage of category scores | ||
| Center for Epidemiologic Studies Depression (CES-D) Scale Score | D-cycloserine | 15.1 | Standard Deviation 6.5 | units on a scale | |
| Center for Epidemiologic Studies Depression (CES-D) Scale Score | Placebo | 9.2 | Standard Deviation 8.8 | units on a scale | |
| Display Enhanced Testing for Concussions and Mild Traumatic Brain Injury (mTBI) (DETECT) System Score | D-cycloserine | 10.2 | Standard Deviation 0.0 | z-score | |
| Display Enhanced Testing for Concussions and Mild Traumatic Brain Injury (mTBI) (DETECT) System Score | Placebo | 10.1 | Standard Deviation 0.1 | z-score |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | D-cycloserine | 7 | |
| Overall Study | STARTED | Placebo | 7 | |
| Overall Study | COMPLETED | D-cycloserine | 7 | |
| Overall Study | COMPLETED | Placebo | 6 | |
| Overall Study | NOT COMPLETED | D-cycloserine | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | D-cycloserine | 0 | 7 |
| Total, all-cause mortality | Placebo | 0 | 7 |
| Total, other adverse events | D-cycloserine | 0 | 7 |
| Total, other adverse events | Placebo | 0 | 7 |
| Total, serious adverse events | D-cycloserine | 0 | 7 |
| Total, serious adverse events | Placebo | 0 | 7 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26587287 | RESULT |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR000454 | Atlanta Clinical and Translational Science Institute (ACTSI) Renewal | STEPHENS, DAVID S | EMORY UNIVERSITY | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2012 to 2016 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| D-cycloserine vs Placebo: deaths from any cause | Trial comparisons |
| D-cycloserine vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02082912
GET https://conductscience.org/api/trials/v1/NCT02082912/registered